MLC901 vs PM012
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Traditional Chinese medicine (multi-component) · full Alzheimer's Disease pipeline
MLC901 · NeuroAiD II
Developed by Moleac Pte Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2029 · NCT07191028 (registry estimate)
No aligned efficacy figure on record for this race.
PM012
Developed by Mediforum Ltd., Co.
NCT05811000 · Phase 2/3 · status unknown
This trial randomized 312 patients with mild Alzheimer's disease to one of three PM012 doses or the standard treatment donepezil, using double-dummy blinding so neither patients nor assessors knew which treatment was given, with cognitive and daily-living scales as the co-primary measures at 12 weeks. No results are posted yet, so it isn't known whether PM012 performed comparably to or better than donepezil.
No aligned efficacy figure on record for this race.
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | MLC901 | PM012 |
|---|---|---|
| CDR-SB, change | —Trial running · NCT07191028 | —Not reported |
| ADAS-Cog11, change | —Trial running · NCT07191028 | —Not reported |
| ADCS-ADL, change | —Trial running · NCT07191028 | —Not reported |
| MMSE, change | —Trial running · NCT07191028 | —Not reported |
| Amyloid PET, change (centiloids) | —Trial running · NCT07191028 | —Not reported |
CDR-SB, change
- MLC901
- —Trial running · NCT07191028
- PM012
- —Not reported
ADAS-Cog11, change
- MLC901
- —Trial running · NCT07191028
- PM012
- —Not reported
ADCS-ADL, change
- MLC901
- —Trial running · NCT07191028
- PM012
- —Not reported
MMSE, change
- MLC901
- —Trial running · NCT07191028
- PM012
- —Not reported
Amyloid PET, change (centiloids)
- MLC901
- —Trial running · NCT07191028
- PM012
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
MLC901: no structured comparison results are available for Alzheimer's Disease.
PM012: no structured comparison results are available for Alzheimer's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MLC901's landscape · PM012's landscape